This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
REVIEW UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
Highlights from SIU Congress 2016
Viewing 1-20 of 32 articles
SIU Congress 2016: Effect of Gonadotrophin-Releasing Hormone Analogue-Induced Follicle-Stimulating Hormone Suppression on Prostate-Specific Antigen Response - Poster
SIU Congress 2016: Bladder cancer: Frailty as a predictor of complications in older patients undergoing radical cystectomy - Session Highlights
SIU Congress 2016: Reclassification in patients candidates for focal therapy: correlation between transrectal biopsy and histology of the lesions observed in mpMRI on radical prostatectomy specimens. - Session Highlights
SIU Congress 2016: Prostate cancer: Prospective study on the correlation between MRI and pathology of radical prostatectomy specimens - Session Highlights
SIU Congress 2016: Bladder cancer: Radical cystectomy in the elderly- is this a safe treatment option? - Session Highlights
SIU Congress 2016: Bladder cancer: Underutilization of radical cystectomy among elderly patients diagnosed with clinical stage T2 muscle-invasive bladder cancer - Session Highlights
SIU Congress 2016: Challenging cases in bladder cancer: High grade T1 bladder cancer: BCG immunotherapy and urine biomarkers of response - Session Highlights
SIU Congress 2016: Is there a good risk muscle invasive bladder cancer? Neoadjuvant chemotherapy for all vs. for high risk only - Session Highlights
SIU Congress 2016: Is there a good risk muscle invasive bladder cancer? Risk factors associated with understaging - Session Highlights
SIU Congress 2016: Is there a good risk muscle invasive bladder cancer? Cross sectional and functional imaging with PET for staging - Session Highlights
SIU Congress 2016: Challenging cases in bladder cancer: High grade T1 bladder cancer: New promising alternatives for patients who fail BCG immunotherapy - Session Highlights
SIU Congress 2016: New therapies and diagnoses in bladder cancer: changing landscape of systemic therapy - Session Highlights
SIU Congress 2016: New therapies and diagnoses in bladder cancer: Emerging strategies in treatment of BCG unresponsive NMIBC - Session Highlights
SIU Congress 2016: New therapies and diagnoses in bladder cancer: Optimal use of novel biomarkers and detection strategies for bladder cancer - Session Highlights
SIU Congress 2016: : Focal therapy for prostate cancer EXPERT REVIEW - Session Highlights
SIU Congress 2016: Shifting Sands: Testicular cancer: Indication for organ-sparing surgery in testicular lesions - Session Highlights
SIU Congress 2016: Shifting Sands: Testicular Cancer: High dose chemotherapy necessary for intermediate prognosis NSGCT? - Session Highlights
SIU Congress 2016: Shifting Sands: Testicular Cancer: Revival of surgery in stage I NSGCT - Session Highlights
SIU Congress 2016: Debate: T2 and T3a bladder cancer: neoadjuvant chemotherapy should be standard - Session Highlights
SIU Congress 2016: Using pathway analysis and metabolic signature to predict survival in MIBC - Session Highlights
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free